5 Results for "

OPRK1

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "OPRK1" in MCE Product Catalog:

Cat. No.: HY-RS09802
Research Areas:  

Others

OPRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for OPRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS27523
Research Areas:  

Others

Oprk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Oprk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
loading...
    loading...
Cat. No.: HY-RS21006
Research Areas:  

Others

Oprk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Oprk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-121800
CAS No.: 1355243-24-1
Research Areas:  

Neurological Disease

ML138 is a blood-brain barrier-permeable κ-opioid receptor (KOR) agonist, with an EC50 value of 0.87 μM and a human Ki value of 2.4 nM for human receptors; it exhibits high selectivity for KOR over μ, δ and other receptors. ML138 activates β-arrestin (beta-arrestin)-mediated signaling pathways, stimulates G protein coupling, and activates the downstream extracellular regulated protein kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAP kinase) signaling pathway. ML138 is applicable to research related to addictive behaviors [1] .
loading...
    loading...
Cat. No.: HY-116163
CAS No.: 1565852-90-5
Synonyms: CYM50202
Target:  

Endogenous Metabolite

Research Areas:  

Others

ML350 (CYM50202) is a highly potent OPRK1 antagonist with selectivity and broad biological applications. With IC50 values of 9-16 nM, ML350 shows high selectivity for OPRK1, with selectivity of 219-382-fold and 20-35-fold relative to OPRD1 and OPRM1, respectively. ML350 exhibited favorable characteristics in in vivo pharmacokinetic analysis, including high passive membrane permeability and moderate human plasma protein binding. Extensive screening of ML350 against multiple ion channels, receptors, and transporters showed that it does not have adverse off-target effects [1].
loading...
    loading...